SCHEMBL1159948

SCHEMBL1159948

O=C(/C=C/c1ccc(O)c(O)c1O)c1cccc(O)c1O

nearest known ligand 0.84

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.61
NR1H4 Q96RI1 2/20 0.61
MAOB P27338 2/20 0.57
BCHE P06276 1/20 0.56
GUSB P08236 1/20 0.56
TERT O14746 1/20 0.54
CHRNA7 P36544 3/20 0.53
CYP1A1 P04798 1/20 0.52
CYP1B1 Q16678 1/20 0.52
IAPP P10997 1/20 0.51
TYR P14679 1/20 0.49
CAPN1 P07384 1/20 0.48
CTSL P07711 1/20 0.48
CTSB P07858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL636137 0.90 BACE1 (0.74) BACE1NR1H4MAOBBCHEGUSB
SCHEMBL7861935 0.84 NR1H4 (0.74) BACE1NR1H4MAOBCYP1A1CYP1B1
SCHEMBL471832 0.81 BCHE (0.77) BACE1NR1H4MAOBBCHEGUSB
SCHEMBL9175439 0.81 TYR (0.77) BACE1CHRNA7TYRCAPN1CTSL
SCHEMBL9175445 0.81 TYR (0.77) BACE1CHRNA7TYRCAPN1CTSL
SCHEMBL30237661 0.79 NR1H4 (0.67) NR1H4MAOBCYP1A1CYP1B1CAPN1
SCHEMBL23610336 0.78 TYR (0.64) MAOBBCHECHRNA7CYP1B1TYR
SCHEMBL471834 0.78 TYR (0.64) MAOBBCHECHRNA7CYP1B1TYR
SCHEMBL27579527 0.78 MAPT (0.77) NR1H4MAOBBCHEGUSBCYP1B1
SCHEMBL11360766 0.78 BACE1 (0.62) BACE1NR1H4MAOBBCHEGUSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008086400-A2 SIRTUIN-ACTIVATING COMPOUNDS OF ENHANCED BIOAVAILABILITY ISP INVESTMENTS INC. (US) 2008-07-17 WO claimed
WO-2018045335-A1 NITROGEN OXIDE DONORS AND USES THEREOF NUSIRT SCIENCES, INC. (US) 2018-03-08 WO disclosed
EP-3197437-A1 COMPOSITIONS, METHODS AND KITS FOR TREATMENT OF DIABETES AND/OR HYPERLIPIDEMIA NuSirt Sciences, Inc. (US) 2017-08-02 EP disclosed
WO-2016049236-A1 COMPOSITIONS, METHODS AND KITS FOR TREATMENT OF DIABETES AND/OR HYPERLIPIDEMIA NUSIRT SCIENCES, INC. (US) 2016-03-31 WO disclosed
US-8475851-B2 Preparations with wood extracts of locust trees SYMRISE AG (DE) 2013-07-02 US disclosed
US-20120195870-A1 PREPARATIONS WITH WOOD EXTRACTS OF LOCUST TREES SYMRISE AG (DE) 2012-08-02 US disclosed
EP-2389922-A1 Cyclohexyl carbamate compounds as anti-ageing actives Symrise AG (DE) 2011-11-30 EP disclosed
WO-2009132050-A9 AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS OTONOMY, INC. (US) 2011-02-03 WO disclosed
US-7592436-B2 Encoding polyphenoloxidases having activity that synthesizes aurones by using chalcones as substrates involved in the color of flowers such as snapdragons; can give yellow color to the flowers of plants by introducing into plants deficient in chalcone isomerase; snapdragons INTERNATIONAL FLOWER DEVELOPMENTS PROPRIETARY LIMITED (AU) 2009-09-22 US disclosed
WO-2008086400-A2 SIRTUIN-ACTIVATING COMPOUNDS OF ENHANCED BIOAVAILABILITY ISP INVESTMENTS INC. (US) 2008-07-17 WO disclosed
EP-1708689-A2 COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS The President and Fellows of Harvard College (US) 2006-10-11 EP disclosed
EP-1001028-B1 GENE ENCODING PROTEIN HAVING AURONE SYNTHESIZING ACTIVITY SUNTORY LTD (JP) 2006-05-31 EP disclosed
US-20060020123-A1 Gene encoding a protein having aurone synthesis activity SUNTORY FLOWERS LIMITED (JP) 2006-01-26 US disclosed
US-6982325-B1 Gene encoding protein having aurone synthesizing activity SUNTORY FLOWERS LIMITED (JP) 2006-01-03 US disclosed
WO-2005065667-A2 COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2005-07-21 WO disclosed
US-6329189-B1 FOR CATALYZING REACTION BETWEEN AN EPOXY RING OF AN EPOXYSUCCINIC ACID AND PHENOLIC HYDROXYL GROUP OF FLAVONOID, OR A FLAVONOID ANALOGOUS COMPOUND TO FORM TARTARIC ACID ETHER WHICH IS USED IN FOOD AND DRUG INDUSTRY KIKKOMAN CORPORATION (JP) 2001-12-11 US disclosed
EP-1001028-A1 GENE ENCODING PROTEIN HAVING AURONE SYNTHESIZING ACTIVITY SUNTORY LIMITED (JP) 2000-05-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120195870-A1 PREPARATIONS WITH WOOD EXTRACTS OF LOCUST TREES LCT, CUTA, GLA BACE1 1568/4885NR1H4 3765/4885MAOB 532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.